Heron Therapeutics | HRTX - Equity Capital And Reserves


Heron Therapeutics reported $13.28M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
ALKERMES USD 1.75B 67.76M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amarin USD 449.41M 9.87M Mar/2026
ANI Pharmaceuticals USD 540.72M 34.91M Dec/2025
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 568.42M 102.37M Dec/2025
Eisai JPY 889.64B 35.21B Dec/2025
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
Merck USD 45.88B 6.73B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 653.89M 39.22M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Surmodics USD 111.31M 7.59M Jun/2025
Ultragenyx Pharmaceutical USD -80M 89.16M Dec/2025
Veracyte USD 1.31B 51.91M Dec/2025
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026